Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Pharmaceuticals Canada said it is “extremely disappointed” that negotiations for Pluvicto, a treatment for patients ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Qatar is to adopt the Cardio4cities approach – a data-driven cardiovascular population health initiative – and become the ...

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the ...